Daniele Pieraccioli - MolMed S Insider

MolMed S p A -- Germany Stock  

EUR 0.41  0.01  2.38%

Director Intellectual Property

Dr. Daniele Pieraccioli Ph.D. serves as Director of Intellectual Property at Molecular Medicine S.p.A. since December 2007. He is Qualified European Patent Attorney with scientific background in Medicinal Chemistry and Biotechnology and is responsible for managing all aspects of intellectual property including evaluation of patentability patent prosecution and freedom to operate through validityinfringement opinions. He has international experience with pharmaceutical and biotech companies including GlaxoSmithKline and Serono. He was Research Scientist for a few years before his professional involvement in the intellectual property. He was involved in the patentee side in patent infringement proceedings on blockbuster drugs as well as in EPO proceedings and litigations in Europe on biotechnological products with final positive outcome of the proceedings. He is Speaker at both national and international Conferences and Author of publications in the field of Intellectual Property. He gained a degree in Chemistry from Universita degli Studi di Firenze and gained a Doctorate in Philosophy from Eidgenossische Technische Hochschule Zurich.
Age: 65  Director Since 2007  Ph.D    

Management Efficiency

The company has return on total asset (ROA) of (18.1) % which means that it has lost $18.1 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (61.21) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 964 K in total debt with debt to equity ratio (D/E) of 6.1 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. MolMed S p A has Current Ratio of 1.37 which is within standard range for the sector.

Similar Executives

Showing few of many executives


Zhongjun FuIndustrial and Commercial Bank
Steven ReinemundWal Mart Stores Inc
Shantanu NarayenPfizer Inc
Qinghui KeIndustrial and Commercial Bank
James CashWal Mart Stores Inc
Shaoxin YangIndustrial and Commercial Bank
Jianian ZhongIndustrial and Commercial Bank
Don CornwellPfizer Inc
Roger CorbettWal Mart Stores Inc
M McCarthyIndustrial and Commercial Bank
Fuqing ZhengIndustrial and Commercial Bank
Suzanne JohnsonPfizer Inc
Michael DukeWal Mart Stores Inc
Timothy FlynnWal Mart Stores Inc
Gangcheng HuangIndustrial and Commercial Bank
James KiltsPfizer Inc
Frances FergussonPfizer Inc
Ronald BlaylockPfizer Inc
Rongrong GeIndustrial and Commercial Bank
Yongmiao HongIndustrial and Commercial Bank
Joseph EchevarriaPfizer Inc

Entity Summary

MolMed S p A (4HW) is traded on Frankfurt Stock Exchange in Germany. and employs 23 people.
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add MolMed S p A to your portfolio

Top Management

MolMed S p Leadership Team
Gian Rizzardi, Director, Ph.D
Marina Bue, Director
Didier Trono, Director
Silvia Pisante, Executive
Mario Masciocchi, Director
Carlo Incerti, Director
Raffaella Ruggiero, Director
Holger Neecke, Director
Luca Alberici, Executive
Maurizio Tassi, Director
Daniele Pieraccioli, Director, Ph.D
Alberto Carletti, Director
Laura Ferro, Director
Marco Dieci, Director, Ph.D
Catia Traversari, Director, Ph.D
Lorenzo Salieri, Director
Elizabeth Robinson, Director
Riccardo Palmisano, CEO
Sabina Grossi, Director, Ph.D
Alfredo Messina, Director
Monica Masolo, Director
Germano Carganico, Executive, Ph.D
Claudio Bordignon, Chairman, Ph.D
Gianluigi Fiorendi, Director
Andrea Quaglino, Director
Khalid Islam, Director, Ph.D
Laura Villa, Director
Cynthia Giuliani, Director
Antonio Lambiase, Director, Ph.D
Marco Manoni, Director
Tiziano Andreoli, Director

Stock Performance

MolMed S Performance Indicators
Return On Equity(61.21) %
Return On Asset(18.1) %
Current Valuation195.6 M
Price to Earning(13.82) times
Price to Book11.53 times
Price to Sales9.28 times
Revenue22.42 M
Gross Profit1000 K
EBITDA(10.6 M)
Net Income(12.02 M)